Assessment of Periprostatic Adipose Tissue via CT as Indicator of Prostate Cancer Severity
Overview
This study evaluated periprostatic fat measured by computed tomography (CT) as a marker for prostate cancer (PC) aggressiveness in 725 men undergoing brachytherapy for localized PC. Findings showed significant associations between CT-measured periprostatic fat density and clinical parameters, with fat density correlating with BMI and other fat measurements, suggesting its potential as a better predictor of PC severity than BMI alone.
Background
Obesity and prostate cancer are major health concerns with a debated relationship; obesity may influence PC aggressiveness. Traditional obesity markers like BMI may not accurately reflect metabolically active fat, particularly visceral fat, which can be better assessed by waist circumference or CT imaging. Adipose tissue secretes hormones and cytokines potentially involved in prostate carcinogenesis, but their exact role remains unclear. This study aimed to investigate whether CT-measured periprostatic fat is a superior marker for PC aggressiveness compared to BMI.
Data Highlights
Characteristic
Fat-Density Group 1 (<25 percentile)
Fat-Density Group 2 (25-75 percentile)
Fat-Density Group 3 (>75 percentile)
Median Age (years)
Lower
Intermediate
Significantly Older
Median Prostate Volume
Statistically different but clinically similar across groups
BMI
Significantly associated with fat-density groups
Subcutaneous Fat Thickness (CFT)
Significantly associated with fat-density groups
Periprostatic Fat Area
Significantly associated with fat-density groups
Key Findings
Periprostatic fat density measured by CT correlates significantly with BMI, subcutaneous fat thickness, and periprostatic fat area.
Patients with higher periprostatic fat density were significantly older.
Median prostate volume differed statistically between fat-density groups but differences were not clinically meaningful.
CT-based fat measurements provide a more precise assessment of visceral fat compared to BMI alone.
Fat-density stratification into percentile groups (<25, 25–75, >75) allowed evaluation of associations with clinical and pathological characteristics.
Clinical Implications
CT measurement of periprostatic fat density offers a more accurate assessment of visceral adiposity related to prostate cancer aggressiveness than BMI. Incorporating CT-based fat quantification could improve risk stratification and guide personalized management in patients with localized prostate cancer. This method may help identify patients at higher risk of aggressive disease who might benefit from closer monitoring or tailored therapeutic approaches.
Conclusion
Periprostatic fat density measured by CT is significantly associated with clinical parameters and may serve as a superior marker for prostate cancer aggressiveness compared to BMI. This novel imaging biomarker warrants further investigation for its role in prostate cancer risk assessment.
References
Ash et al. 2006 -- Risk classification in prostate cancer
D’Amico et al. 1998 -- Prostate cancer risk stratification
